この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
規制と法律 · 2025/12/231 分で読めます
Prospective Grant of an Exclusive Patent License: Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1, or TRAT1
ローカル自動翻訳 · 情報源の原言語
概要
The Eunice Kennedy Shriver National Institute of Child Health and Human Development, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to EnZeta Immunotherapies, Inc., a company located in Coral Gables, FL.
情報源の原言語: Federal Register — All Documents原文の発表を開く →